385 related articles for article (PubMed ID: 34783946)
1. Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Tonello M; Baratti D; Sammartino P; Di Giorgio A; Robella M; Sassaroli C; Framarini M; Valle M; Macrì A; Graziosi L; Coccolini F; Lippolis PV; Gelmini R; Deraco M; Biacchi D; Santullo F; Vaira M; Di Lauro K; D'Acapito F; Carboni F; Giuffrè G; Donini A; Fugazzola P; Faviana P; Sorrentino L; Scapinello A; Del Bianco P; Sommariva A
Ann Surg Oncol; 2022 Jun; 29(6):3405-3417. PubMed ID: 34783946
[TBL] [Abstract][Full Text] [Related]
2. Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients.
Larsen SG; Goscinski MA; Dueland S; Steigen SE; Hofsli E; Torgunrud A; Lund-Iversen M; Dagenborg VJ; Flatmark K; Sorbye H
Br J Cancer; 2022 Mar; 126(5):726-735. PubMed ID: 34887523
[TBL] [Abstract][Full Text] [Related]
3. RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases.
Bhullar D; O'Dwyer S; Wilson M; Saunders MP; Kochhar R; Barriuso J; Aziz O
Ann Surg Oncol; 2023 Feb; 30(2):792-801. PubMed ID: 36400886
[TBL] [Abstract][Full Text] [Related]
4. Impact of Primary Tumor Location and Genomic Alterations on Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Colorectal Peritoneal Metastases.
Hamed AB; Shuai Y; Derby J; Holtzman MP; Ongchin M; Bartlett DL; Pingpank JF; Pai R; Singhi A; Choudry HA
Ann Surg Oncol; 2023 Jul; 30(7):4459-4470. PubMed ID: 37085655
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC.
Graf W; Cashin PH; Ghanipour L; Enblad M; Botling J; Terman A; Birgisson H
Ann Surg Oncol; 2020 Jan; 27(1):293-300. PubMed ID: 31571052
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of specific KRAS mutations in patients with colorectal peritoneal metastases.
Tonello M; Baratti D; Sammartino P; Di Giorgio A; Robella M; Sassaroli C; Framarini M; Valle M; Macrì A; Graziosi L; Coccolini F; Lippolis PV; Gelmini R; Deraco M; Biacchi D; Aulicino M; Vaira M; De Franciscis S; D'Acapito F; Carboni F; Milone E; Donini A; Fugazzola P; Faviana P; Sorrentino L; Pizzolato E; Cenzi C; Del Bianco P; Sommariva A
ESMO Open; 2024 Apr; 9(4):102976. PubMed ID: 38613907
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
8. The impact of molecular and mismatch repair status on the survival outcomes of surgically treated patients with colorectal peritoneal metastases.
Flood MP; Jain A; Mitchell C; Hewitt C; Ramsay R; Michael M; Heriot AG; Tie J
Eur J Surg Oncol; 2022 Oct; 48(10):2218-2225. PubMed ID: 35750576
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases.
Baratti D; Kusamura S; Niger M; Perrone F; Milione M; Cattaneo L; Guaglio M; Bartolini V; Pietrantonio F; Deraco M
Ann Surg Oncol; 2021 Jun; 28(6):3332-3342. PubMed ID: 32974694
[TBL] [Abstract][Full Text] [Related]
10. Is Systemic Chemotherapy Useful in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Metastases? A Propensity-Score Analysis.
Tonello M; Baratti D; Sammartino P; Di Giorgio A; Robella M; Sassaroli C; Framarini M; Valle M; Macrì A; Graziosi L; Coccolini F; Lippolis PV; Gelmini R; Deraco M; Biacchi D; Santullo F; Vaira M; Di Lauro K; D'Acapito F; Carboni F; Milone E; Donini A; Fugazzola P; Faviana P; Sorrentino L; Pizzolato E; Cenzi C; Del Bianco P; Sommariva A
Ann Surg Oncol; 2024 Jan; 31(1):594-604. PubMed ID: 37831280
[TBL] [Abstract][Full Text] [Related]
11. ASO Author Reflections: Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Tonello M; Sommariva A
Ann Surg Oncol; 2022 Jun; 29(6):3418-3419. PubMed ID: 34743279
[No Abstract] [Full Text] [Related]
12. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review.
Chow FC; Yip J; Foo DC; Wei R; Choi HK; Ng KK; Lo OS
Asian J Surg; 2021 Jan; 44(1):221-228. PubMed ID: 32605790
[TBL] [Abstract][Full Text] [Related]
13. Mutations of RAS/RAF Proto-oncogenes Impair Survival After Cytoreductive Surgery and HIPEC for Peritoneal Metastasis of Colorectal Origin.
Schneider MA; Eden J; Pache B; Laminger F; Lopez-Lopez V; Steffen T; Hübner M; Kober F; Roka S; Campos PC; Roth L; Gupta A; Siebenhüner A; Kepenekian V; Passot G; Gertsch P; Glehen O; Lehmann K
Ann Surg; 2018 Nov; 268(5):845-853. PubMed ID: 30303876
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy.
Zhou S; Jiang Y; Liang J; Pei W; Zhou Z
World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
[TBL] [Abstract][Full Text] [Related]
16. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis].
Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170
[No Abstract] [Full Text] [Related]
17. Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases.
Ljunggren M; Nordenvall C; Palmer G
Eur J Surg Oncol; 2021 Nov; 47(11):2865-2872. PubMed ID: 34116900
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.
Won DD; Lee JI; Lee IK; Oh ST; Jung ES; Lee SH
BMC Cancer; 2017 Jun; 17(1):403. PubMed ID: 28583095
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Molecular Features in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Colorectal Cancer.
Di Giorgio A; Santullo F; Attalla El Halabieh M; Lodoli C; Abatini C; Calegari MA; Martini M; Rotolo S; Pacelli F
J Gastrointest Surg; 2021 Oct; 25(10):2649-2659. PubMed ID: 34244953
[TBL] [Abstract][Full Text] [Related]
20. The role of molecular biomarkers in outcomes and patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases of colorectal origin.
Solomon D; Leigh N; Bekhor E; Feferman Y; Dhorajiya P; Feingold D; Hofstedt M; Aycart SN; Golas BJ; Sarpel U; Labow DM; Magge DR
Surgeon; 2021 Dec; 19(6):e379-e385. PubMed ID: 33423919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]